NorthlineHealth
Join
← FormularyTracking · Category 2

GHRH Analogue · Long-Acting

CJC-1295

GH axis, recovery

Status
On watchlist — not yet prescribable
Get notified on reclassification

Mechanism

CJC-1295 is a tetrasubstituted 30-amino-acid peptide analogue of GHRH with drug affinity complex (DAC) technology that binds covalently to albumin, extending half-life from minutes to 6–8 days. It produces sustained elevation of GH and IGF-1, amplifying natural GH pulses rather than creating a continuous flat elevation.

Indications

→GH axis support and IGF-1 elevation
→Lean body mass and fat reduction
→Recovery and tissue repair
→Often stacked with ipamorelin (GHRP) for synergistic effect

Regulatory status

CJC-1295 (with DAC) is on the FDA 503A Category 2 list. CJC-1295 without DAC (Mod GRF 1-29) has a different regulatory standing. Northline does not prescribe either form until reclassification and monitors status.

References

01Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295. J Clin Endocrinol Metab. 2006.
02FDA 503A Category 2 — ineligible for compounding.

This fact sheet is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Compounded medications are not FDA-approved. Prescribing decisions are made by a licensed clinician based on individual medical necessity. Not all patients qualify.